Research programme: anti-cancer immunotherapies - University College London/Tusk Therapeutics/Cancer Research Technology

Drug Profile

Research programme: anti-cancer immunotherapies - University College London/Tusk Therapeutics/Cancer Research Technology

Latest Information Update: 14 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University College London
  • Developer Cancer Research Technology; Tusk Therapeutics; University College London
  • Class Antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 07 Feb 2017 Cancer Research Technology, University College London, and Tusk Therapeutics agree to research, develop and commercialise antibody-based immunotherapies in United Kingdom for cancer
  • 07 Feb 2017 Tusk Therapeutics agree to fund preclinical antibody therapeutics co-developed by University College London and Cancer Research Technology in United Kingdom for Cancer
  • 07 Feb 2017 Early research in Cancer in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top